WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults
1 dicembre 2025
Leggi
Breaking news
AIFA: Verso un modello fast-track per l’autorizzazione di studi clinici multinazionali nell’UE/SEE
28 novembre 2025
Leggi
Effect of semaglutide on insulin sensitivity and cardiometabolic risk factors in adolescents with obesity: the STEP TEENS study
Arslanian S, Gies I, Goldman B, et al.
Diabetes Care. Pub. online 26 Nov 2025.
Leggi
Sensory network dysregulation in type 2 diabetes: linking olfactory, visual, and cognitive function
Li Q, Li X, Bi Y, et al.
Diabetes Obes Metab. Pub. online 25 Nov 2025.
Leggi
Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation
Maya J, Pant D, Fu Y, et al.
JAMA. Pub. online 24 Nov 2025.
Leggi
A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events
Riveline JP, Julla JB, Bonnemaison E, et al.
Diabetes Obes Metab. Pub. online 24 Nov 2025.
Leggi
Tirzepatide in adults with type 1 diabetes: a phase 2 randomized placebo-controlled clinical trial
Snaith JR, Frampton R, Samocha-Bonet D, Greenfield JR
Diabetes Care. Pub. online 20 Nov 2025.
Leggi
Ultra-processed foods and human health: the main thesis and the evidence
Monteiro CA, Louzada ML, Steele-Martinez E, et al.
Lancet. Pub. online 18 Nov 2025.
Leggi
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England
Zaccardi F, Ling S, Gillies CL, et al.
Lancet Diabetes Endocrinol. Pub. online 19 Nov 2025.
Leggi
Metabolic improvement mediates the causal relationship between GLP-1 receptor agonists and myocardial infarction: a mendelian randomization and mediation analysis study
Tong J, Li N, Hu F, Yue Y
Diabetes Care. Pub. online 19 Nov 2025.
Leggi